Silihan lan utang jangka dawa perusahaan: kiorapharma.com (KPRX)

Kiora Pharmaceuticals (KPRX) ensures the supply of ophthalmological agents through climate-controlled cold chains, guaranteeing stable revenue and drug availability. The stock's price history reflects the dynamics of a business creating innovative biologics for vision restoration with the support of Western partners. Growth potential is driven by the shortage of therapies for orphan retinal pathologies, and the current metric stands at 0.00, highlighting the issuer's market opportunities.

The development of orphan drugs for eye treatment is independent of market cycles, relying exclusively on clinical trial results. This metric aggregates all credit obligations of Kiora Pharmaceuticals (KPRX) with maturities exceeding twelve months. It measures the long-term financial burden, determining the biotech's degree of dependence on external borrowing. Debt reduction strengthens autonomy, whereas an increase signals credit risks. By analyzing the firm's level of long-term borrowed funds, an investor assesses the sustainability of the scaling strategy.